Business Wire India

Leading indigenous unmanned combat systems manufacturer, Johnnette Technologies Pvt. Ltd., has announced the signing of a strategic Memorandum of Understanding (MoU) with Munitions India Limited (MIL), a premier Defence Public Sector Undertaking (DPSU) under the Ministry of Defence, Government of India. The public-private defence partnership marks a significant stride toward complete self-reliance in cutting-edge aerial weapon systems.

Under the terms of the landmark agreement, Johnnette Technologies and MIL will jointly collaborate on the tactical integration of advanced warheads for Johnnette’s flagship JM series Loitering Munitions platforms, as well as its upcoming Unmanned Combat Aerial Vehicle (UCAV) programs.

Strengthening the Indigenous Defence Ecosystem

As India aggressively modernizes its armed forces amid evolving geopolitical challenges, this collaboration bridges private-sector aerospace innovation with state-owned defence infrastructure. By combining Johnnette’s combat-proven autonomous flight technologies with MIL’s world-class ordnance manufacturing infrastructure and explosive chemical expertise, the partnership targets a 100% indigenous supply chain for next-generation precision-strike munitions.

Key Strategic Verticals of the MoU.

• Next-Gen Integration: Outfitting the Johnnette JM-series loitering munitions and upcoming tactical combat drones with indigenous lethal payloads.
• Aatmanirbhar Bharat Acceleration: Lowering dependence on foreign military components by substituting imported assemblies with custom domestic alternatives.

“We are deeply honored and privileged to partner with Munitions India Limited. This collaboration directly supports the vision of #AatmanirbharBharat by ensuring our armed forces receive mission-ready, highly lethal combat solutions built entirely within the country,” said Lt Cdr John Livingstone (Retd.), Founder, Chairman & CEO of Johnnette Technologies. “We extend our gratitude to the leadership at MIL for their trust. The future of Indian defence aviation is autonomous, indigenous, and powerful.”

Business Wire India

‘SMEs are the engine that create a new economy,’ said Prof Ram Charan, global advisor to CEOs while addressing entrepreneurs, business leaders, and professionals at the Leadership Conclave on ‘Leadership That Delivers’ recently organised by WPU Goa in association with BNI Goa Region.

The conclave was one of the initiatives by WPU Goa for industry outreach and industry capacity building, particularly for SMEs and emerging business leaders in Goa. WPU Goa is a future-focused university built on the principles of transdisciplinary learning, experiential pedagogy, and continuous interaction with industry leaders, entrepreneurs, policymakers, and practitioners to prepare students for the evolving global landscape. The initiative reflects WPU Goa’s belief that universities must play an active role not only in educating students, but also in strengthening leadership capacity, innovation ecosystems, and entrepreneurial growth within the larger economy.

As a globally respected advisor to CEOs, boards, and institutions, Prof. Ram Charan continues to engage with WPU Goa as a mentor, thought partner, and part of the university’s broader leadership and core visioning group. During the leadership deep-dive session at the conclave, Prof. Ram Charan highlighted that learning must continuously enhance an individual’s ‘capacity’ to grow, lead, and adapt in rapidly changing business environments. Stressing the importance of scalable leadership for SMEs, he advised entrepreneurs to focus on ‘clarity,’ ‘specificity and actions,’ and long-term conviction while building organisations.

Speaking extensively on business growth and execution, he said that founders must ‘focus on a few things, go into depth, get them done,’ rather than attempting too many priorities simultaneously. He further emphasised that businesses should ‘build processes that will expand your capacity’ instead of remaining dependent entirely on the founder. Highlighting the need for organisational evolution, he encouraged leaders to ‘delegate,’ ‘automate,’ and ‘digitize’ in order to scale sustainably.

Drawing examples from global business leaders, Prof Ram Charan noted that successful entrepreneurs build conviction around their vision and attract capable talent despite uncertainty and limited resources. He stated that entrepreneurs should have the courage to recruit ‘people better than you’ who can ‘raise the bar’ and help organisations grow beyond the founder’s personal bandwidth.

Addressing SME founders on practical business challenges, he highlighted key issues including access to financing, attracting experienced professionals, delegation, prioritisation, and resistance to change. Encouraging continuous learning and mentorship, he advised entrepreneurs to move beyond ‘buzzwords’ and focus on execution, learning habits, and disciplined leadership practices that create long-term value.

Speaking on the role of education in nation-building and leadership, Dr. Rahul Karad founder WPU Goa, emphasised that universities must become ‘centers for transformation of the country’ and create an ‘open environment’ rooted in India’s value systems. He further stressed that education, cinema, media, sports, and spiritual leaders collectively shape society, adding that ‘universities only can really set the direction’ for future generations and national transformation.

Speaking about Goa’s development and the university’s vision for the state, Dr Ashish Bhardwaj, Pro Vice Chancellor, WPU GOA said, “Goa presents itself as a vibrant, multicultural, agile economy where global thinking stands in harmony with local wisdom and traditional knowledge. For us, Goa is a living lab of new ideas, progress, sustainability, and shared prosperity. WPU Goa is deeply committed to lead the transformation in higher education with the support, engagement, and expertise of Goa’s business leaders and communities to strengthen the social, cultural, and financial ecosystem and economy of Goa.”

The event also featured the WPU Goa Leadership Excellence Awards, where distinguished SME and corporate leaders were felicitated for their contribution to business, innovation, and leadership. Through these awards, WPU Goa seeks to acknowledge leaders who are not only driving enterprise growth but also contributing to regional transformation, innovation ecosystems, and broader societal progress, reinforcing the university’s commitment to building stronger connections between academia, industry, and emerging leadership.

Later in the day, former Group President and Chief Technology Officer of Anand Group, Sunil Kaul, spoke on leadership for MSMEs and stressed that business success comes from understanding problems deeply and converting challenges into opportunities. He highlighted the importance of learning through failures, maintaining financial discipline, and focusing on ethical governance and the ‘quality of profit.’

Speaking on ‘Leadership for Sustainable Growth,’ Mr Ashwini Malhotra, Vice Chairman, Weikfield Food Pvt Ltd said that leadership must guide organisations toward ‘long-term success, and not just short-term profits,’ while balancing economic growth, environmental sustainability, and social responsibility. He noted that ‘true economic value is created due to ethical values,’ adding that ethical leadership builds trust, goodwill, and sustainable profitability.

Through the conclave, WPU Goa highlighted its vision of building stronger industry-academia partnerships with industry leaders, management thinkers, entrepreneurs, and practitioners to nurture future-ready talent, leadership capabilities, and innovation-driven growth ecosystems for Goa and the broader business community.

Business Wire India

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526487212/en/

 

 

 

Built on Biocytogen’s proprietary RenMice^® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery.

 

RenSuper Workstation: AI-Powered One-Click Target-to-Lead Therapeutic Antibody Discovery

 

 

RenSuper Workstation introduces a new paradigm for one-click therapeutic antibody discovery, transforming antibody discovery from a project-based workflow into a searchable and programmable system. The platform enables rapid identification of high-quality therapeutic candidates with strong developability, functional relevance, and translational potential.

 

 

Proprietary Fully Human Antibody Library

 

 

The platform provides off-the-shelf access to fully human antibody sequences against more than 1,000 validated targets, complete with data packages to support more confident decision-making.

 

 

AI-Powered Candidate Selection

 

 

RenSuper’s AI models are trained on more than 100 million biologically validated antibody sequences, enabling efficient candidate identification against structurally and biologically challenging targets.

 

 

Using Biocytogen’s RenNano^® fully human HCAb platform as an example, the AI-powered screening workflow achieved an average positive hit rate of 46%, with peak hit rates reaching 98%. The workflow also enriched candidates with superior developability profiles and delivered an 82% success rate for high-purity (≥90%) Fc-format antibody expression.

 

 

Experimentally Validated Antibody Sequences

 

 

All AI-selected antibody sequences undergo experimental validation, including binding, affinity, and specificity characterization, ensuring reproducibility, reliability, and downstream development readiness.

 

 

One-Click Search & Design

 

 

The platform enables one-click filtering and comparison of antibody candidates by target, epitope, and physicochemical properties. An integrated antibody design platform further supports rapid sequence assembly and flexible format design across multiple therapeutic modalities.

 

 

Learn more about RenSuper Workstation: https://www.rensuperbio.com/

 

 

RenSuper High-Throughput Automation Center

 

 

Beyond intelligent discovery, RenSuper integrates industrial-scale automation to establish a scalable, closed-loop antibody development engine.

 

 

The newly launched automation center enables high-throughput experimental validation of AI-selected antibody candidates with minimal manual intervention, significantly accelerating the transition from molecular design to functional evaluation.

 

 

The fully automated platform spans the entire protein production workflow, including bacterial inoculation, plasmid extraction, transfection, fed-batch cultivation, and purification.

 

 

The system consistently delivers antibody yields averaging 50-100 mg, with throughput of up to 800 samples per day and over 5,000 samples per week, transforming antibody validation from a labor-intensive process into a scalable industrial workflow.

 

 

“We believe the future of antibody discovery will be driven by speed, scale, and data-driven intelligence,” said Dr. Yuelei Shen, Founder and CEO of Biocytogen. “With RenSuper, we are building an intelligence-native system that makes antibody discovery more intelligent, scalable, and efficient. Our goal is to reduce the time and complexity of early-stage discovery, accelerate the development of innovative therapeutics, and bring new medicines to patients faster.”

 

 

Together, RenSuper Workstation and the RenSuper High-Throughput Automation Center establish a next-generation target-to-lead ecosystem powered by biologically validated immune repertoires, artificial intelligence, and industrial-scale automation.

 

 

This milestone further reinforces Biocytogen’s vision of becoming the “Global Headstream of New Drugs” by transforming therapeutic antibody discovery into a more intelligent, scalable, and programmable process for biologics innovation worldwide.

 

 

About Biocytogen

 

 

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

 

 

Biocytogen has independently developed its proprietary RenMice^® (RenMab^®/RenLite^®/RenNano^®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526487212/en/

 

Business Wire India

Mevion Medical Systems has signed a definitive purchase agreement to bring the MEVION S250-FIT Proton Therapy System™ to Tam Anh General Hospital in Vietnam. This would be the first proton therapy system in Vietnam. This signing reflects a broader shift in cancer care: proton therapy is becoming more practical to deploy, enabling more hospitals to bring advanced treatment closer to the patients who need it. Both the MEVION S250-FIT™ and MEVION S250i Proton Therapy System® have recently received regulatory approval in Vietnam, marking an important step toward clinical implementation.

 

The introduction of proton therapy at Tam Anh General Hospital marks a turning point for cancer care in Southeast Asia and is facilitated by TD Tech Company, Mevion’s distributor in Vietnam. By establishing this domestic capability, Vietnam joins a growing group of countries expanding access to advanced proton therapy, ensuring that Vietnamese patients have access to world-class treatment within their own borders. The MEVION S250-FIT system at Tam Anh General Hospital is expected to become operational as early as late 2027, upon the inauguration of Tam Anh’s new facility in Phu My Hung, one of Vietnam’s most modern urban areas.

 

 

Proton therapy is widely regarded as one of the most advanced forms of radiation treatment available today. Unlike conventional photon (X-ray) radiation therapy, proton beams can precisely deposit the majority of their energy directly within the tumor while minimizing exit dose beyond the target. This level of precision reduces radiation exposure to healthy tissues and helps lessen treatment-related side effects in select clinical scenarios, particularly for complex tumors and pediatric cancers.

 

 

MEVION S250-FIT™: Making Proton Therapy a Reality

 

 

The cornerstone of this partnership is the MEVION S250-FIT, a breakthrough technology designed to make proton therapy a practical reality for hospitals worldwide. Historically, proton therapy required massive, multi-story facilities and decade-long planning cycles. The FIT™ platform changes this paradigm, enabling advanced care to be deployed with unprecedented ease:

 

 

• Bunker-Ready Design: It is the only FDA-cleared proton system designed for installation in a standard, existing radiation therapy vault.
• Rapid Deployment: By eliminating the need for massive new construction, the FIT allows hospitals to begin treating patients much faster than traditional systems.
• Operational Simplicity: The FIT system fits directly into conventional oncology workflows, using AI-driven treatment planning and integrated diagnostic CT imaging.
• Upright Patient Positioning: The installation will feature an upright patient positioning system from Leo Cancer Care, providing enhanced flexibility in patient setup and a more comfortable experience for those treated in a seated position.
• State-of-the-art Treatment Planning: Powered by RaySearch Laboratories, the RayStation®* treatment planning system features multi-criteria optimization, HYPERSCAN® and DirectARC™ planning, and highly accurate dose engines tailored specifically for advanced proton therapy.

 

 

Leadership Vision

 

“Our partnership with Tam Anh General Hospital marks an important step in Mevion’s mission to make the most advanced cancer care accessible to patients worldwide,” said Tina Yu, Ph.D., CEO and President of Mevion Medical Systems. “By integrating the MEVION S250-FIT into their oncology program, Tam Anh is demonstrating how the next generation of compact proton therapy can be seamlessly adopted by leading health systems to deliver precise, life-saving treatment closer to home.”

 

 

“As one of Vietnam’s leading general hospital systems in terms of clinical excellence, advanced and specialized technologies, and comprehensive services, Tam Anh has consistently taken the lead in acquiring world-class, cutting-edge medical technologies and equipment,” said Mr. Ngo Chi Dung, Chairman of the Board of Directors, Tam Anh General Hospital Group. “The purchase of the next-generation MEVION S250-FIT™ Proton Therapy System marks a significant milestone, not only for the Tam Anh General Hospital Group but also as a major step forward in Vietnam’s efforts to access and effectively deploy the world’s most advanced medical technologies in cancer care. This event reaffirms Tam Anh’s strategic vision of making large-scale, comprehensive investments in healthcare in general, and oncology in particular, serving millions of Vietnamese people as well as international patients, in alignment with international standards of quality, clinical effectiveness, and patient safety.”

 

 

About Mevion Medical Systems

 

 

Mevion Medical Systems is a leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion’s series of products, including the flagship MEVION S250i^® and MEVION S250-FIT™ with HYPERSCAN^® pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia. For more information, please visit www.mevion.com.

 

 

About Tam Anh General Hospital Group

 

 

Tam Anh General Hospital Group is a high-tech hospital system delivering advanced diagnostics and treatment, specialized care, and training and research meeting international standards. After a decade of development, the Tam Anh General Hospital Group has become one of Vietnam’s leading modern private healthcare systems. The system currently operates five facilities in Hanoi and Ho Chi Minh City, serving more than two million patient visits each year, including tens of thousands of international patients. For more information, please visit: https://tamanhhospital.vn.

 

 

About TD Tech Company

 

 

Toan Dien Medical Technology Company Limited (TD Tech Company) is a medical device distributor in Vietnam with more than twenty years of experience in the field of radiation oncology. For more information, please visit: https://xatri.vn.

 

 

*RaySearch products are subject to regulatory clearance in some markets.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526647140/en/

 

Business Wire India

Omdia’s latest research reveals that Europe’s smartphone market (excluding Russia) grew 2% to 33.0 million units in 1Q26, showing resilience amid growing supply-side costs and increasing risks of availability bottlenecks. Healthy end-user demand alongside channel frontloading helped boost the market.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526611788/en/

 

 

 

Key vendor highlights from 1Q26 include:

 

• Samsung was Europe’s largest vendor as it grew 3% to 12.6 million units. Effective discounting of the Galaxy A16 4G helped Samsung boost volume, offsetting declines related to the delayed launch of the Galaxy S26, A57 and A37.
• Apple grew 9% to 8.8 million iPhones, driven by robust iPhone 17 series demand in addition to benefiting from a wider mid-range coverage from the iPhone 15 and iPhone 16e. Noticeably, Apple’s strong results came despite lower and fewer discounts than in previous years.
• Xiaomi retained third place despite declining 15% to 4.5 million units, as it was more immediately impacted by supply-side difficulties. However, Xiaomi’s ASP grew 21% compared with 1Q25, boosted by a record-strong Xiaomi 17 and 15T series performance, which drove year-on-year value growth despite the shipment decline. Premium sales were particularly strong in France, Germany, and Spain.
• Motorola grew 17% to 1.9 million units, driven by rapid expansion in Spain and Portugal, alongside continued progress in France and Italy.
• OPPO grew 9% to 1.3 million units, largely driven by its comeback in France alongside growth in Romania and Poland. With both realme and OnePlus now under its umbrella, OPPO is restructuring to optimize its portfolio and strategy with ambitions to strengthen its European position.
• HONOR, ranking sixth, was the fastest-growing vendor among the largest players, with shipments increasing more than 60% compared to 1Q25. HONOR’s growth is underpinned by its portfolio being expanded further down the price-tiers.

 

“Demand remains healthy in Europe’s smartphone market as shipments were boosted by the ongoing replacement wave alongside channel partners expanding their inventories,” said Runar Bjorhovde, Principal Analyst at Omdia. “Even though some price hikes have occurred, combined with fewer and lower discounts than in previous years, vendors and channel partners remain far more concerned about what is to come in 2Q26. In a region where the three largest vendors hold almost 80% market share, competition is often fiercer amongst channel partners than between vendors, creating a clear rationale for the channel to frontload as a precautionary move.”

 

“The average-selling-price (ASP) of smartphones in Europe surged to a record-high level of €580 in 1Q26,” added Bjorhovde. “This was largely caused by lower availability of devices costing less than €200, which made up an all-time low of just 25% of shipments. Additionally, the high-end remained resilient thanks to Apple’s growth. The focus from both vendors and channel partners has shifted from volume to value to deliver results and operational sustainability. Many vendors who normally focus on the mass market segments are increasingly concentrating on the mid-to-high-end, hoping to benefit from less price-sensitive and upgrade-willing buyers.”

 

 

“The first quarter of 2026 delivered beyond expectations, but the outlook remains bearish as the rapidly escalating memory bottleneck worsens,” commented Bjorhovde. “Omdia forecasts shipments into Europe to decline 12% in 2026, but the majority of this will come in the second half of the year. We expect inventory levels to remain above normal as long as the trajectory points to future steep price increases. However, a market correction will be inevitable in the mid-term, as it will become beneficial to act cautiously and reduce inventory levels again as memory pricing starts to stabilize. Both vendors and channel partners need to remain highly agile within the evolving market conditions but must ensure that their focus remains upon attracting end-buyers and strengthening their brands for long-term success.”

 

 

Europe (excl. Russia) smartphone shipments (market share and annual growth)   Omdia Smartphone Market Pulse: 1Q26
Vendor	1Q26 shipments (millions)	1Q26 market share	1Q25 shipments (millions)	1Q25 market share	Annual growth
Samsung	12.6	38%	12.2	38%	+3%
Apple	8.8	26%	8.0	25%	+9%
Xiaomi	4.5	14%	5.3	16%	-15%
Motorola	1.9	6%	1.7	5%	+17%
OPPO	1.3	4%	1.2	4%	+9%
Others	4.0	12%	4.1	13%	-2%
Total	33.1	100%	32.4	100%	+2%
Note: Xiaomi includes Redmi and POCO. OPPO includes realme and OnePlus Percentages may not add up to 100% due to rounding. Source: Omdia Smartphone Horizon Service (sell-in shipments), May 2026

 

ABOUT OMDIA

 

Omdia, part of TechTarget, Inc. d/b/a Informa TechTarget (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets grounded in real conversations with industry leaders and hundreds of thousands of data points, make our market intelligence our clients’ strategic advantage. From R&D to ROI, we identify the greatest opportunities and move the industry forward.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526611788/en/

 

Business Wire India

Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today announced the launch of direct operations in India, including a dedicated local sales and service team based in Gurugram, near New Delhi. The launch, marked with a ribbon-cutting ceremony, is an important milestone in the company’s geographical expansion and reinforces its commitment to serving customers in one of the world’s most dynamic and fastest-growing life sciences markets.

 

For over a decade, Tecan has supported customers in India through its trusted distributor partner Bioscreen. As it establishes a direct presence, Tecan will continue to work with Bioscreen, combining local expertise with closer customer engagement and strengthened support.

 

 

The establishment of Tecan India, incorporated on April 1, 2026, brings the company closer to customers across the pharmaceutical, biotechnology, academic and diagnostic sectors, enabling more direct collaboration and responsive local support.

 

 

Mukta Acharya, EVP and Head of Tecan’s Life Sciences business, said:“India is a key market for the future of life sciences, with strong momentum across CROs, pharma, biotech and diagnostics. Establishing a direct presence allows us to be closer to our customers, deepen collaboration and further strengthen the value we deliver locally.”

 

 

Building on its expansion into South Korea in 2024, Tecan is strengthening its presence in high-growth regions as part of its ongoing commitment to improving the lives and health of people. It does this by enabling its customers to scale healthcare innovation globally.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526195832/en/